Back to top

Analyst Blog

Halozyme Therapeutics, Inc. (HALO - Snapshot Report) was a big mover last session, as the company saw its shares advance nearly 7% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. This continues the recent uptrend for this biotechnology company as the stock is now up more than 53% in the past one month time frame.

The company has seen 6 negative revisions in the past few weeks and its earnings consensus has moved down over the past two months, suggesting there may be trouble down the road for HALO. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Halozyme currently has a Zacks Rank #3 (Hold) and its Earnings ESP is positive.

Some better performing biotechnology stocks include Affymetrix Inc. (AFFX - Analyst Report), Agenus Inc. (AGEN - Snapshot Report) and Alkermes plc (ALKS - Analyst Report). Affymetrix carries a Zacks Rank #1 (Strong Buy), while Agenus and Alkermes carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Please login to Zacks.com or register to post a comment.